Literature DB >> 29752258

How and when I do allogeneic transplant in CLL.

John G Gribben1.   

Abstract

Allogenic stem cell transplantation (allo-SCT) has been considered the treatment of choice for high-risk patients with chronic lymphocytic leukemia (CLL) and the only approach offered with curative intent in this disease. The availability novel agents, including the B-cell receptor inhibitors ibrutinib, acalabrutinib, and idelalisib, as well as venetoclax, which targets the BCL2 pathway, and the success of these agents in treating high-risk disease patients have made it more difficult to assess who should be considered for allo-SCT and when in the treatment course. In this review, I will discuss the different treatment options available for the treatment of high-risk CLL and how allo-SCT fits into the treatment algorithm in the era of novel agents.
© 2018 by The American Society of Hematology.

Entities:  

Mesh：

Substances：

Year:  2018        PMID： 29752258      PMCID： PMC6034643          DOI： 10.1182/blood-2018-01-785998

Source DB:  PubMed          Journal:  Blood        ISSN： 0006-4971            Impact factor:   22.113


  64 in total

1.  Risk categories and refractory CLL in the era of chemoimmunotherapy.

Authors:  Thorsten Zenz; John G Gribben; Michael Hallek; Hartmut Döhner; Michael J Keating; Stephan Stilgenbauer
Journal:  Blood       Date:  2012-03-06       Impact factor: 22.113

2.  Long-term remissions after FCR chemoimmunotherapy in previously untreated patients with CLL: updated results of the CLL8 trial.

Authors:  Kirsten Fischer; Jasmin Bahlo; Anna Maria Fink; Valentin Goede; Carmen Diana Herling; Paula Cramer; Petra Langerbeins; Julia von Tresckow; Anja Engelke; Christian Maurer; Gabor Kovacs; Marco Herling; Eugen Tausch; Karl-Anton Kreuzer; Barbara Eichhorst; Sebastian Böttcher; John F Seymour; Paolo Ghia; Paula Marlton; Michael Kneba; Clemens-Martin Wendtner; Hartmut Döhner; Stephan Stilgenbauer; Michael Hallek
Journal:  Blood       Date:  2015-10-20       Impact factor: 22.113

Review 3.  How I treat CLL up front.

Authors:  John G Gribben
Journal:  Blood       Date:  2009-10-22       Impact factor: 22.113

Review 4.  How should we sequence and combine novel therapies in CLL?

Authors:  Matthew S Davids
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2017-12-08

5.  Impact of drug development on the use of stem cell transplantation: a report by the European Society for Blood and Marrow Transplantation (EBMT).

Authors:  J R Passweg; H Baldomero; P Bader; C Bonini; S Cesaro; P Dreger; R F Duarte; C Dufour; J Kuball; D Farge-Bancel; A Gennery; N Kröger; F Lanza; A Nagler; A Sureda; M Mohty
Journal:  Bone Marrow Transplant       Date:  2016-11-07       Impact factor: 5.483

6.  Multiple inhibitory ligands induce impaired T-cell immunologic synapse function in chronic lymphocytic leukemia that can be blocked with lenalidomide: establishing a reversible immune evasion mechanism in human cancer.

Authors:  Alan G Ramsay; Andrew J Clear; Rewas Fatah; John G Gribben
Journal:  Blood       Date:  2012-04-30       Impact factor: 22.113

7.  Ibrutinib efficacy and tolerability in patients with relapsed chronic lymphocytic leukemia following allogeneic HCT.

Authors:  Christine E Ryan; Bita Sahaf; Aaron C Logan; Susan O'Brien; John C Byrd; Peter Hillmen; Jennifer R Brown; Martin J S Dyer; Anthony R Mato; Michael J Keating; Samantha Jaglowski; Fong Clow; Andrew R Rezvani; Lori Styles; Steven E Coutre; David B Miklos
Journal:  Blood       Date:  2016-11-01       Impact factor: 22.113

8.  Targeting BCL2 with Venetoclax in Relapsed Chronic Lymphocytic Leukemia.

Authors:  Andrew W Roberts; Matthew S Davids; John M Pagel; Brad S Kahl; Soham D Puvvada; John F Gerecitano; Thomas J Kipps; Mary Ann Anderson; Jennifer R Brown; Lori Gressick; Shekman Wong; Martin Dunbar; Ming Zhu; Monali B Desai; Elisa Cerri; Sari Heitner Enschede; Rod A Humerickhouse; William G Wierda; John F Seymour
Journal:  N Engl J Med       Date:  2015-12-06       Impact factor: 91.245

9.  Ibrutinib enhances chimeric antigen receptor T-cell engraftment and efficacy in leukemia.

Authors:  Joseph A Fraietta; Kyle A Beckwith; Prachi R Patel; Marco Ruella; Zhaohui Zheng; David M Barrett; Simon F Lacey; Jan Joseph Melenhorst; Shannon E McGettigan; Danielle R Cook; Changfeng Zhang; Jun Xu; Priscilla Do; Jessica Hulitt; Sagar B Kudchodkar; Alexandria P Cogdill; Saar Gill; David L Porter; Jennifer A Woyach; Meixiao Long; Amy J Johnson; Kami Maddocks; Natarajan Muthusamy; Bruce L Levine; Carl H June; John C Byrd; Marcela V Maus
Journal:  Blood       Date:  2016-01-26       Impact factor: 22.113

10.  Single-agent ibrutinib in treatment-naïve and relapsed/refractory chronic lymphocytic leukemia: a 5-year experience.

Authors:  Susan O'Brien; Richard R Furman; Steven Coutre; Ian W Flinn; Jan A Burger; Kristie Blum; Jeff Sharman; William Wierda; Jeffrey Jones; Weiqiang Zhao; Nyla A Heerema; Amy J Johnson; Ying Luan; Danelle F James; Alvina D Chu; John C Byrd
Journal:  Blood       Date:  2018-02-02       Impact factor: 25.476
View more
  21 in total

Review 1.  Relapsed CLL: sequencing, combinations, and novel agents.

Authors:  Jennifer R Brown
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2018-11-30

2.  Allogeneic haematopoietic cell transplantation impacts on outcomes of mantle cell lymphoma with TP53 alterations.

Authors:  Richard J Lin; Caleb Ho; Patrick D Hilden; Juliet N Barker; Sergio A Giralt; Paul A Hamlin; Ann A Jakubowski; Hugo R Castro-Malaspina; Kevin S Robinson; Esperanza B Papadopoulos; Miguel-Angel Perales; Craig S Sauter
Journal:  Br J Haematol       Date:  2018-12-11       Impact factor: 6.998

3.  Chronic lymphocytic leukemia: from molecular pathogenesis to novel therapeutic strategies.

Authors:  Julio Delgado; Ferran Nadeu; Dolors Colomer; Elias Campo
Journal:  Haematologica       Date:  2020-07-02       Impact factor: 9.941

4.  No longer too exhausted to run.

Authors:  John G Gribben
Journal:  Blood       Date:  2018-08-02       Impact factor: 22.113

Review 5.  Inhibiting Bruton's Tyrosine Kinase in CLL and Other B-Cell Malignancies.

Authors:  Fabienne Lucas; Jennifer A Woyach
Journal:  Target Oncol       Date:  2019-04       Impact factor: 4.493

6.  Relapsed disease and aspects of undetectable MRD and treatment discontinuation.

Authors:  Barbara Eichhorst; Moritz Fürstenau; Michael Hallek
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2019-12-06

7.  Venetoclax plus rituximab or obinutuzumab after allogeneic hematopoietic stem cell transplantation in chronic lymphocytic leukemia.

Authors:  Othman Al-Sawaf; Carmen Diana Herling; Udo Holtick; Christoph Scheid; Paula Cramer; Stephanie Sasse; Bastian von Tresckow; Armin Tuchscherer; Kirsten Fischer; Barbara Eichhorst; Michael Hallek; Lukas P Frenzel
Journal:  Haematologica       Date:  2019-02-21       Impact factor: 9.941

Review 8.  Targeted Drug Delivery for Chronic Lymphocytic Leukemia.

Authors:  Makhloufi Zoulikha; Wei He
Journal:  Pharm Res       Date:  2022-03-07       Impact factor: 4.200

9.  Reduced-intensity conditioning hematopoietic stem cell transplantation for chronic lymphocytic leukemia and Richter's transformation.

Authors:  Oscar B Lahoud; Sean M Devlin; Molly A Maloy; Lindsey E Roeker; Parastoo B Dahi; Doris M Ponce; Boglarka Gyurkocza; Guenther Koehne; James W Young; Hugo R Castro-Malaspina; Juliet N Barker; Esperanza B Papadopoulos; Ann A Jakubowski; Andrew D Zelenetz; Anthony R Mato; Sergio A Giralt; Miguel A Perales; Craig S Sauter
Journal:  Blood Adv       Date:  2021-07-27

Review 10.  NK Cells in Chronic Lymphocytic Leukemia and Their Therapeutic Implications.

Authors:  Paolo Sportoletti; Filomena De Falco; Beatrice Del Papa; Stefano Baldoni; Valerio Guarente; Andrea Marra; Erica Dorillo; Chiara Rompietti; Francesco Maria Adamo; Loredana Ruggeri; Mauro Di Ianni; Emanuela Rosati
Journal:  Int J Mol Sci       Date:  2021-06-22       Impact factor: 5.923
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.